Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + nab-paclitaxel + iparomlimab-tuvorilimab for advanced gallbladder cancer
ChiCTR2600117584Phase 2Not yet recruiting
- Sponsor
- Xinhua Hospital
- Start
- Jan 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, nab-paclitaxel, iparomlimab and QL1706 in gallbladder cancer, sponsored by Xinhua Hospital. Primary endpoints: Surgical conversion rate, Objective response rate (ORR) and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
gemcitabinenab-paclitaxeliparomlimabQL1706
03
Conditions
gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2600117584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117584.